Create accountLogin

Recent searches

No recent searches

Search options

Only available when logged in.
shakedown.social is one of the many independent Mastodon servers you can use to participate in the fediverse.
A community for live music fans with roots in the jam scene. Shakedown Social is run by a team of volunteers (led by @clifff and @sethadam1) and funded by donations.

Administered by:

Server stats:

291
active users

shakedown.social: AboutStatusProfiles directoryPrivacy policy

Mastodon: AboutGet the appKeyboard shortcutsView source codev4.3.4

#pharma

2 posts2 participants0 posts today
Continued thread
Public *
petersuber

Update. New study: "#NIH investment in drugs approved from 2010 to 2019 was not less than investment by the #pharmaceutical industry, with comparable accounting for basic and applied research, failed clinical trials, and cost of capital or discount rates."
jamanetwork.com/journals/jama-

PS: Relevant to (1) #Trump admin cutbacks to NIH #funding and (2) industry #patents and licensing terms on approved drugs.

#Medicine#Pharma
Public
Ken Hallenbeck

Excited to share the first paper from my team at Merck. Sometimes, in vitro translation systems like mRNA display make mistakes - but does it happen often enough to matter?

chemistry-europe.onlinelibrary

Yes, it does. We describe how you can measure and control the imperfections inherent to genetic reprogramming and IVT in order to design more effective screening libraries in your hunt for the next peptide drug.

#pharma#biotech#science
Public
Industry Documents Library

The #OpioidCrisis isn’t just a US problem. A BBC investigation helped prompt India to ban a harmful mix of #opioid tapentadol and muscle relaxant carisoprodol that Indian #pharma company Aveo was illegally exporting to countries in West Africa and fueling a #PublicHealth crisis

bbc.com/news/articles/cdx2vwg8

www.bbc.comIndia bans two drugs behind opioid crisis in West AfricaThe moves come after a BBC investigation found a firm had been illegally exporting the drugs.
Public
MEZIS e.V.

Wenn wir unsere Bremsen nicht vom TÜV sondern von den Bremsenherstellern selbst kontrollieren lassen würden, wären höhere Ausgaben für Bremsen wahrscheinlich. Machen wir deshalb nicht.

Wenn bei der europäischen Leitlinie für Herzschrittmacher 88% dieser Autoren Gelder von im Schnitt fünf Herstellern eben dieser Geräte bekommen ... sind höhere Ausgaben für Herzschrittmacher zu erwarten. Sollten wir auch nicht machen!

Deshalb haben wir von #Leitlinienwatch diese europäische Leitlinie mit miesen 3/18 Punkten bewertet:

leitlinienwatch.de/2021-esc-gu

www.leitlinienwatch.deleitlinienwatch.de - 2021 ESC Guidelines on cardiac pacing and cardiac resynchronization therapyLeitlinienwatch ist ein Portal zur Bewertung medizinischer Leitlinien im Hinblick auf ihre Unabhängigkeit von der Pharmaindustrie.
#pharma#mezis
Public
Miguel Afonso Caetano

"China’s biotech boom mirrors its rise in tech. In both cases, China has moved up the value chain, from manufacturing goods to becoming a more sophisticated hub for innovation, competing in industries once dominated by the U.S. There are several reasons for the industry’s growth. For one, many top scientists trained in the U.S. have returned to China over the past decade, fueling the emergence of biotech hubs around Shanghai. And just as DeepSeek built a formidable chatbot—allegedly on a lean budget with limited access to semiconductors—Chinese biotech companies are also scrappier, capitalizing on a highly skilled, lower-cost workforce that can move faster.

Additionally, companies can conduct clinical trials at a fraction of what they would cost in the U.S., while recent changes in the Chinese regulatory system have streamlined and accelerated the approval process to get a study started.

For now, much of China’s biotech innovation is incremental rather than groundbreaking. Many companies focus on improving existing drugs—tweaking the chemistry, enhancing efficacy or differentiating them in key ways.

But Chinese innovation is steadily improving and is already starting to disrupt the U.S. drug-development ecosystem. For decades, the U.S. biotech industry has thrived in hubs such as Boston-Cambridge and the San Francisco Bay Area, fueled by talent streaming from top academic centers like Massachusetts Institute of Technology and Stanford University. Those biotech companies have an insatiable client in Big Pharma, which is willing to pay top dollar for new drugs to replace those going off-patent."

wsj.com/health/pharma/the-drug

#China#BioTech#DrugIndustry
Public
Ken Hallenbeck

My little science game released today! This is a small contribution to making what we do in pharma & biotech seem less foreign and more fun, in a time when making life-saving drugs is increasingly maligned in the public square.

Give it a download if you can - I appreciate the support :)

iOS:
apps.apple.com/us/app/research
Android:
play.google.com/store/apps/det

Hand pick a team of lab experts
Use random events to your advantage
Decide how to upgrade your lab
....And more!
#science#pharma#biotech
Public
Brittany Trang

AI “looks like magic” to Owkin's Andy Pierce, despite the fact that he works at the “first end-to-end AI biotech.”

But his traditional pharma background helps him articulate how AI is _actually_ helpful in planning clinical trials.

I learned a lot:

@STAT statnews.com/2025/01/30/owkin-

STAT · How AI helps drug developers skirt pharma’s ‘dirty little secret’Andrew Pierce, senior executive at French biotech Owkin, on how artificial intelligence can make the drug development process more efficient.
#health#healthcare#medicine
ExploreLive feeds
About